Pharming N.V.(PHAR) - 2023 Q2 - Earnings Call Transcript

And then, of course, the third pillar there on that slide is, of course, as important, if not more, for the – let's say, for the future significant inflection point that we believe that we can achieve with leniolisib, that is the second indication. And we, as you may have read already, have been already submitting our plans and have initiated discussions with the FDA on how – on our proposed development program for the second indication and Anurag will come back to that a little bit later. And next slide, p ...